Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REVEAL: Imaging and Blood Biomarker EValuation of Engraftment After ALlogeneic Hematopoietic Stem Cell Transplantation
NCT03541889Phase 1Recruiting
- Sponsor
- University of Oklahoma
- Start
- Oct 2020
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 1, open-label trial of fluorothymidine F-18 in primary graft failure (PGF) (2 cohorts), sponsored by University of Oklahoma. Primary endpoint: FLT Standardized Uptake Value identifies graft failure. Started Oct 2020; status: recruiting.
02
Drugs
fluorothymidine F-18
03
Conditions
primary graft failure (PGF)
Beyond the preview
Go deeper on NCT03541889.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03541889.